Michael Henderson

Michael Henderson has over 8 years of experience in the healthcare and biotechnology industries. Michael began their career in 2014 as a Summer Associate at McKinsey & Company, followed by an Associate Intern role at GE Ventures in 2014. In 2015, they joined McKinsey & Company as a Senior Associate where they focused on inorganic growth through M&A, drug discovery, and commercial strategy. In 2016, they joined BridgeBio as VP of Asset Acquisition, Strategy, & Operations, and was promoted to SVP of Asset Acquisition, Strategy, & Operations in 2017. Michael also served as a Member of the Board of Directors for Adrenas Therapeutics and Quartz Therapeutics in 2017, and TheRas Therapeutics in 2016. In 2018, they were appointed as CBO of Origin Biosciences, a subsidiary of BridgeBio Pharma. In 2022, Michael was appointed as Chief Executive Officer at Apogee Therapeutics.

Michael Henderson received their MD from Stanford University School of Medicine with a concentration in Health Policy. Michael also attended Harvard University for a Global Health degree and Stanford University Graduate School of Business for its Ignite Program.